Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Vaxart Inc VXRT

Vaxart, Inc. is a clinical-stage biotechnology company that is primarily focused on the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) proprietary oral vaccine platform. Its vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Its development programs include pill vaccines designed to protect against norovirus (cause for acute gastroenteritis), coronavirus, including SARS-CoV-2 (COVID-19)), and influenza. In addition, it has generated preclinical data for its therapeutic vaccine candidate targeting cervical cancer and dysplasia caused by human papillomavirus. The Company's platform technology employs a vector-based approach and consists of various components, such as a vector (adenovirus type 5 (Ad5); an antigen (Ad5 DNA); an adjuvant (Toll-like receptor 3 (TLR3)), and its proprietary enteric-coated tablet.


NDAQ:VXRT - Post by User

<< Previous
Bullboard Posts
Next >>
Post by thevisionary2kon Feb 12, 2021 8:32am
326 Views
Post# 32550159

VXRT - Institutional Investors

VXRT - Institutional Investors

Let’s put into perspective the VXRT-State Street, BlackRock and Vanguard investments - three (3) of largest asset management and investment firms in the world with $18 Trillion in Assets.

 

State Street:

  • Total Assets: $3.2 Trillion
  • VXRT Shares: 9.5 Million
  • VXRT Share % Change: 33,072%
  • Current VXRT Market Value: $81.8 Million

 

BlackRock

  • Total Assets: $8.7 Trillion
  • VXRT Shares: 4.9 Million
  • VXRT Share % Change: 645%
  • Current VXRT Market Value: $42.8 Million

 

Vanguard Group

  • Total Assets: $6.2 Trillion
  • VXRT Shares: 5.0 Million
  • VXRT Share % Change: 27%
  • Current VXRT Market Value: $43.3 Million

 

Combined, the Current VXRT Market Value is $167.9 Million, equating to 20.4 million shares owned, while their VXRT share percentage change ranges from 27% - 33,072%.

 

State Street, BlackRock and Vanguard would not have increased its investments in VXRT without performing proper due diligence.

<< Previous
Bullboard Posts
Next >>